Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune and Neuroinflammatory Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for S1PR1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Full-Length GPCR | S1PR1 Lentivirus Premade Particles HEK293 Expressed, Native Glycosylation, For Stable Cell Line Generation. Sequence Verified. |
View S1PR1 Products |
| Mutant Antigen | S1PR1 Mutant Antigens (dbSNP variants rs4987250, rs11542632, rs7549921) Theoretical MW Verified, High Purity (>95%), Endotoxin <1EU/ug. |
View S1PR1 Products |
| Gene Delivery | S1PR1 Promise-ORF Lentiviral Vector Codon-optimized ORF for stable expression in CHO/HEK293 cells. |
View S1PR1 Products |
| Benchmark Ab | Anti-S1PR1 Monoclonal Antibody (Reference Clone) Recombinant positive control for binding/competition assays. |
View S1PR1 Products |
| Validator | S1PR1 siRNA Set (3 unique sequences) For knockdown verification and specificity controls. |
View S1PR1 Products |
| Selectivity Screen 1 | S1PR3/EDG3 Ortholog protein for cardiac safety counter-screening (avoid S1PR3 mediated bradycardia). |
View S1PR3 Products |
| Selectivity Screen 2 | S1PR5/EDG8 Family member for CNS penetration/receptor subtype analysis. |
View S1PR5 Products |
| Pathway Partner | SPHK1 (Sphingosine Kinase 1) Upstream enzyme controlling S1P ligand synthesis; synergistic target. |
View SPHK1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GPCR Conformational Integrity for Functional Assays | Full-Length S1PR1 Lentivirus in HEK293 Cells preserves native glycosylation and 7-TM topology; suitable for calcium flux and cAMP assays. |
| Selectivity vs S1PR3 (Cardiac Safety / Bradycardia Risk) | Human/Mouse/Cyno S1PR1 and S1PR3 ortholog protein panel available; strict sequence verification by mass spec for off-target liability assessment. |
| Receptor Internalization Kinetics (ADC Development) | High-titer S1PR1 Lentivirus (>10^8 TU/mL) enables stable high-expression cell lines for quantitative Flow Cytometry internalization assays. |
| Biased Signaling Characterization | Compatible with G-protein vs β-arrestin recruitment assays using S1PR1 stable cell lines with Endotoxin-controlled reagents. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) and siRNA validation sets included for assay standardization. |
Live S1PR1/EDG1/CD363 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for S1PR1 therapeutics is intensifying, with major players shifting focus from pan-S1P receptor modulators to highly selective S1PR1 antagonists. Following the success of fingolimod (non-selective) and the emergence of next-generation modulators like ponesimod (S1PR1-selective), the field is pivoting toward biased signaling modulators that preserve immune suppression while minimizing cardiac liabilities associated with S1PR3 activation. First-generation therapies like fingolimod paved the way, and the next wave of R&D is intensely focused on enhancing receptor subtype selectivity to eliminate cardiovascular side effects (e.g., bradycardia linked to S1PR3). Future developments are exploring highly selective S1PR1/S1PR5 modulators, expanding indications into neurodegeneration, alopecia, and novel immune-oncology combinations. The field is also targeting Inflammatory Bowel Disease (IBD), Systemic Lupus Erythematosus (SLE), and solid tumor immunotherapy combinations.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| S1PR1-Selective Small Molecules | Novartis, Bristol Myers Squibb, Johnson & Johnson | Multiple Sclerosis, Ulcerative Colitis | Selectivity Assays (Need S1PR1 vs S1PR3 vs S1PR5 Ortholog Panels to assess bradycardia risk) |
| Biased Agonists / Functional Antagonists | Actelion (J&J), Arena Pharmaceuticals | Autoimmune Hepatitis, Psoriasis | β-arrestin Recruitment Assays (Need stable S1PR1 cell lines with native coupling) |
| Anti-S1PR1 Antibodies / ADCs | Emerging Biotechs (Stealth Mode) | Lymphoid Malignancies, Solid Tumors | Internalization Assays (Need high-expression S1PR1 lentivirus for Flow Cytometry) |
| Combination Immunotherapy | Incyte, Merck | Oncology (PD-1 combos) | S1PR1/S1PR5 Dual Cell Lines (Tumor microenvironment penetration studies) |
| Targeted Protein Degrader | Academic/Biotech | Refractory Autoimmune | Degradation Validation (Need Sequence-verified ORF) |